Pharvaris BV (PHVS NASDAQ) stock market data APIs
$23.9358
0.14(0.6%)
as of September 17, 2025
Try our APIs with
free plan!
Pharvaris BV Financial Data Overview
Price chart is built with
Anychart
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), as well as in Phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Prev. Close
23.9358
Open
24.0807
High
24.9548
Low
23.5984
52 wk Range
11.51-26.33
Market Cap
1 531 M
Shares Outstanding
64 300 K
EPS
-0.83
Beta
-2.804
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Pharvaris BV (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Pharvaris BV data using free add-ons & libraries
Get Pharvaris BV Fundamental Data
Pharvaris BV Fundamental data includes:
- Net Revenue:
- EBITDA: -165 502 608
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-12
- EPS/Forecast: -0.7686
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Pharvaris BV News
New
Pharvaris stock price target lowered to $52 by Citizens JMP
Investing.com - Citizens JMP lowered its price target on Pharvaris B.V. (NASDAQ:PHVS) to $52.00 from $55.00 on Wednesday, while maintaining a Market Outperform rating on the stock. Currently trading a...
Pharvaris NV (NASDAQ:PHVS) Reports Wider Q2 2025 Loss, Highlights Clinical Trial Progress
PHARVARIS NV (NASDAQ:PHVS [https://www.chartmill.com/stock/quote/PHVS]) REPORTS Q2 2025 EARNINGS: WIDER LOSS THAN EXPECTED, CLINICAL PROGRESS IN FOCUS Pharvaris NV (NASDAQ:PHVS [https://www.chartmill...
Pharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
ZUG, Switzerland, July 24, 2025 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists t...
Pharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Pharvaris N.V. ZUG, Switzerland, July 24, 2025 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
